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ABSTRACT
Lung cancer (LC) is a serious public health problem responsible for the majority 
of cancer deaths and comorbidities in developed countries. Tobacco smoking is 
considered the main risk factor for LC; however, only a few smokers will be affected 
by this cancer. Current screening methods are focused on identifying the early stages 
of this malignancy. Thus, new data concerning the roles of microRNA alterations in 
inflammation, epithelial-mesenchymal transition and lung disease have increased 
hope about LC pathogenesis, diagnosis, treatment and prognosis. MicroRNA 
mechanisms include angiogenesis promotion, cell cycle regulation by modulating 
cellular proliferation and apoptosis, and migration and invasion inhibition. In this 
context, this manuscript reviews the current information about many important 
microRNAs as they relate to the initiation and progression of LC.
INTRODUCTION
Lung cancer (LC) is the most common cause of 
cancer death, with a high incidence and mortality in both 
genders. Despite progress in research regarding new 
targets, therapeutics, and strategies for LC screening and 
early diagnosis, prognosis is still poor, and overall survival 
rates remain low [1, 2]. LC can be divided in two types: 
small cell lung cancer (SCLC) with a neuroendocrine 
origin and non-small cell lung cancer (NSCLC). NSCLC 
accounts for approximately 80% of all LC and includes 
both squamous cell cancer and adenocarcinoma [2]. 
The main risk factor for LC is tobacco use; however, 
only a small percentage of smokers will develop LC 
(approximately 10% of all smokers), suggesting that 
other factors are also involved, such as individual genetic 
variations [3].
Recent data demonstrated the importance of 
regulatory mechanisms at the transcriptional level, such as 
gene regulation by small non-coding RNAs (microRNAs). 
These mechanisms include regulation of genes that 
mediate processes such as inflammation, the cell cycle, 
stress responses, differentiation, apoptosis and invasion. 
In this context, research regarding the involvement 
of microRNAs in LC tumorigenesis is increasing as 
the search for new biomarkers and therapeutic targets 
continues [1, 2]. Thus, the main objective of this brief 
review is to summarize the current information about the 
role of microRNAs in inflammation associated with the 
initiation and progression of LC.
MicroRNAs
MicroRNAs are small, noncoding RNA molecules, 
20-25 nucleotides in length, that negatively regulate 
gene expression at the post-transcriptional level. These 
molecules are encoded by specific genes and function 
in repressing mRNA translation or promoting mRNA 
degradation. MicroRNAs play an important role in many 
biological processes, such as inflammation, cell growth, 
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apoptosis, development, differentiation, endocrine 
homeostasis and even cancer [4].
It is known that microRNAs are involved in lung 
inflammatory mechanisms, epithelial-mesenchymal 
transition, and, consequently, in LC development and 
therapy response. The potential applications of microRNAs 
in cancer diagnostics and prognostics, and as therapeutic 
targets have led to an increased interest in this research area 
[5]. The effects of microRNAs on cytokine signaling are 
based on transcription factors, cytokines and modulators of 
cytokine signaling. In addition, cytokine signaling is crucial 
in the differentiation of many immune cells. Thus, the role 
of microRNAs in immune cell differentiation is based on the 
regulation of cytokine expression and the regulation of their 
downstream signaling components. Several studies have 
shown that microRNAs, including miR-21, have an important 
role in balancing Th1 and Th2 responses to antigens 
[6, 7]. At present, the most studied microRNAs are miR-494, 
let-7, miR-155, miR-135b, miR-21, miR-125b, miR-196 and 
miR-210 [5].
miR-494 can be produced by lung cancer cells 
leading to tumor angiogenesis. In a hypoxic environment, 
this angiogenic process promotes tumor development 
through HIF-1α-induced upregulation of miR-494 [8]. 
On the other hand, miR-494 downregulates cellular 
proliferation in LC. It was demonstrated that constitutive 
expression of miR-494 in A549 lung cancer cells leads 
to the suppression of cell proliferation and induction of 
senescence. It was also demonstrated that insulin-like 
growth factor 2 mRNA-binding protein 1 (IGF2BP1) 
could be a target of miR-494. It was demonstrated that 
IGFBP1 has a role in carcinogenesis development and 
regulation by binding to mRNAs coding IGF2 (Insulin-
like growth factor 2) and c-Myc [9]. In the A549 lung 
cancer cell line, miR-155 modulates cellular apoptosis and 
DNA damage through an Apaf-1-mediated pathway [10]. 
miR-153 inhibits the migration and invasion of human 
NSCLC by targeting ADAM19 and producing anti-tumor 
activity in LC through AKT suppression (Table 1) [11, 12].
Another microRNA involved in cell proliferation 
and survival pathways, which is frequently altered in 
tumors, is Let-7. This microRNA is overexpressed during 
cell cycle progression and functions as a key regulator 
of several genes involved in cell proliferation. It is also 
known that reduced expression of the Let-7 family 
molecules in LC is associated with a poor survival rate. 
Furthermore, Let-7 directly regulates several proto-
oncogenes involved in cell cycle regulation, such as RAS, 
CDC25A, CDK6 and cyclin D [13]. Thus, Let-7 controls 
cell proliferation by impairing the G1 to S transition [4]. 
MicroRNAs and epithelial-mesenchymal 
transition (EMT)
EMT is a complex process that allows a polarized 
epithelial cell to go through several biochemical changes, 
ultimately assuming a mesenchymal cell phenotype. These 
changes increase cell migratory capacity, invasiveness, 
resistance to apoptosis and production of extracellular 
matrix components. Thus, EMT is crucial for epithelial 
cancer invasion and metastasis [25]. A strong correlation 
between EMT and the migratory and invasive capacity of 
tumor cells has been demonstrated. These mesenchymal-
like cancer cells and TGF-β-induced EMT cells are 
characterized by increased invasive abilities compared to 
epithelial-like cancer cells. Thus, EMT is a key factor in 
the facilitation of tumor migration and invasion [26]. 
Several microRNAs have been described as 
important regulators of EMT, and their dynamic roles 
in the balance between EMT and the reverse process, 
termed mesenchymal to epithelial transition (MET), are 
recognized. One of these microRNAs is miR-153, which 
is downregulated in the TGF-β-induced mesenchymal 
phenotype of epithelial cancer cells [25]. 
Additionally, ectopic expression or targeted 
‘knockdown’ of miR-153 resulted in downregulation 
or increased expression of SNAI1 (Snail Family Zinc 
Finger 1) and ZEB2 (Zinc Finger E-Box Binding 
Homeobox 2) protein levels, respectively. These two 
transcription factors promote the repression of the 
adhesion molecule E-cadherin to regulate EMT during 
embryonic development. In fact, SNAI1 and ZEB2 are 
considered critical pro-metastatic factors for their EMT-
inducing capabilities [26, 27]. These studies also defined 
SNAI1 and ZEB2, both of which serve as transcriptional 
repressors of E-cadherin through binding with E-box 
elements in the E-cadherin promoter, as direct targets of 
miR-153. Therefore, E-cadherin is a key factor in EMT 
since its expression is decreased in the cells that undergo 
EMT in the presence of miR-153 inhibitors. Thus, the 
downregulation of miR-153 is crucial for the acquisition 
or maintenance of mesenchymal cell morphology and 
contributes to the EMT-associated carcinoma cell invasion 
induced by TGF-β [26]. 
Regarding the miRNAs that are related to 
the promotion of EMT and development of LC, the 
downregulated miR-200 family controls transcriptional 
factors such as Zinc Finger E-Box-Binding Homeobox 
(ZEB), E-cadherin and vimentin [20]. miR-218 also has an 
important role in the regulation of EMT-related traits and 
the metastasis of LC, in part by modulating Slug/ZEB2 
signals [23] (Table 1). Increasing evidence has shown 
other miRNAs, including miR-124, miR-135a, miR-148a 
and miR-193a-3p/5p, to be powerful suppressors of EMT 
that are often downregulated in LC (for review see [28]).
Cytokines and inflammatory cells, inflammation 
and lung cancer
Chronic inflammation, a key promoting factor of 
lung tumorigenesis, is associated with the secretion of 
cytokines, including tumor necrosis factor α (TNF-α), 
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interleukin (IL) 1, IL-6, IL-8, and molecules such 
as cyclooxygenase-2 (COX-2), that are defined as 
“alarm cytokines” due to their roles in the initiation of 
inflammation. These cytokines are produced by normal 
cells, tumor cells and cellular components of the tumor 
microenvironment [5, 29]. TNF-α serves as an important 
factor in the initiation and regulation of the cytokine 
signaling cascade by triggering the release of IL-1β and 
IL-6 [29]. IL-1β is a pro-inflammatory cytokine that 
belongs to the interleukin-1 family, which is composed of 
several members, including IL-1α and IL-1R antagonist 
(IL-1Ra), an inhibitor of preformed IL-1β. It was 
demonstrated that a variable number of the IL-1Ra gene is 
not an independent risk factor for NSCLC, but it can play 
a role in prognosis when combined with polymorphisms of 
the IL-1β gene [3]. IL-6 and IL-8 play different roles at the 
systemic level, and both are inducible by IL-1β [30]. IL-6 
stimulates secretion of C-reactive protein, an important 
inflammatory biomarker (Figure 1). 
IL-1β is also directly involved in the regulation of 
plasma levels of C-reactive protein by gene regulation 
and indirectly involved through the production of several 
pro-inflammatory molecules, including COX-2, inducible 
nitric oxide synthase, and IL-6, among other cytokines. 
High levels of IL-1β in the tumor microenvironment are 
directly associated with a poor prognosis mainly because 
IL-1β promotes tumor invasiveness by angiogenesis 
induction and the activation of myeloid-derived suppressor 
cells and M2 macrophages [29, 31].
IL-1β inhibits miR-101, a tumor-suppressive 
microRNA, via the COX-2-HIF1α pathway [17]. The role 
of COX-2 in the initiation and progression of NSCLC is 
already recognized. It was demonstrated that knockdown 
of COX-2 significantly increased miR-101 expression, 
showing that COX-2 negatively controls miR-101 
expression in NSCLC cells. Previous studies also showed 
that IL-1β activates HIF1α through the NF-κB/COX-2 
pathway. HIF1α is a transcriptional repressor for miR-101 
via IL-1β interactions in NSCLC. It was demonstrated 
that IL-1β promotes the activation of NF-κB, which 
transcriptionally activates Lin28B. This protein coding 
gene represents a key link the inflammation associated 
with cancer cell transformation and is a novel target of 
miR-101. Thus, Lin28B is upregulated by repression of 
miR-101 (IL-1β). It was concluded that downregulation 
of miR-101 by IL-1β is a key mechanism in the promotion 
of carcinogenesis and the development of malignant 
processes [5, 18].
miR-101 is also related to IL-1β via Enhancer of 
Zeste 2 Polycomb Repressive Complex 2 Subunit (EZH2), 
a member of the polycomb-group family that form 
multimeric protein complexes, including the complex 
involved in the methylation of histone H3. Several 
studies demonstrated the upregulation of EZH2 in LC, 
and it is postulated that this upregulation promotes tumor 
development and progression by dysregulation of the cell 
cycle [15]. The first study that proposed the role of the 
IL-1β/miR-101/EZH2 axis in LC found that autocrine 
and paracrine IL-1β stimulated the downregulation 
of miR-101 in a Xuanwei LC cell line (XWLC-05), 
leading to EZH2 upregulation, which in turn triggered 
tumorigenesis [16]. 
Table 1: Key microRNAs in lung cancer
miRNAs Gene targets Biological mechanisms References
miR-494 IGF2BP1 Promotes angiogenesis and decreases cellular 
proliferation
[8, 9]
Let-7 RAS, CDC25A, CDK6, cyclin D, LIN28, 
MYC, HMGA2, HOXA9, TGFBR1, 
BCL-XL, MAP4K3
Represses cell proliferation and regulates the 
cell cycle 
[4, 13]
miR-155 hexokinase 2, APAf-1 Promotes glucose metabolism, modulates 
cellular apoptosis and DNA damage response
[10, 14]
miR-153 ADAM19, AKT Inhibits the migration and invasion of human 
non-small cell lung cancer, inhibits proliferation 
and migration, and promotes the apoptosis of 
cultured lung cancer cells
[11, 12]
miR-101 COX-2, Lin28B, EZH2 Inhibits cell proliferation, inflammation, and 
dysregulation of the cell cycle
[15–18]
miR-135b IL-1R1 Mediates the inflammatory response [19]
miR-200 ZEB, E-cadherin, vimentin Promotes EMT [20, 21]
miR-218 Slug/ZEB2, tumor protein D52 Inhibits cell migration, invasion and EMT [22, 23] 
miR-487b SUZ12, BMI1, WNT5A, MYC, KRAS Represses the proliferation and invasion of LC 
cells
[24]
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miR-135b expression is regulated by IL-1R1, 
a direct target of miR-135b, during IL-1R1/IL-1α-
mediated inflammation. By using IL-1R1 knockout 
mice, it was demonstrated that miR-135b expression is 
IL-1R1 dependent. Furthermore, in vitro activation of the 
IL-1R1 pathway in mouse embryonic fibroblasts and lung 
epithelial cells resulted in increased miR-135b levels. 
Thus, there is a negative feedback loop in which IL-1R1 
and miR-135b self-regulate one another. In addition, to 
decrease the inflammation induced by cigarette smoke, 
miR-135b regulates IL-1R1 expression by targeting its 
downstream mediators, Caspase-1 and IL-1β [19]. 
Cigarette smoke: alterations on microRNAs
The identification of differentially expressed 
microRNAs between the non-malignant tissues of current 
smokers and the non-malignant tissues of individuals 
who had never smoked suggests that smoking history 
plays an important role in microRNA expression. It was 
hypothesized that the altered expression of microRNAs 
in the non-malignant tissues of current smokers affects 
distinct cellular pathways and may be an early event in 
smoking-associated tumorigenesis [32]. Finding the 
same pattern of differentially expressed microRNAs may 
differentially influence LC prognosis and may represent 
an important marker for therapeutic intervention. For 
example, in a specific smoking status group, miR-
195, miR-138 and miR-150 demonstrated aberrant and 
recurrent expression, and were significantly associated 
with the survival rate of this group [32].
Experimental data provided evidence that exposure 
to various environmental or lifestyle factors, such as 
environmental cigarette smoke, result in extensive 
alterations to miRNA expression in the lung. The 
expression of 484 miRNAs was analyzed in rat lungs 
after exposure to environmental cigarette smoke for 
28 days, which led to the downregulation of 126 of 
these miRNAs [33]. Most miRNAs are downregulated 
in tumors when compared to normal tissues because of 
the association between microRNA levels and cellular 
differentiation. Thus, the reduction of microRNA 
expression in cancer cells is associated with their degree 
of cellular differentiation, and consequently, the reduction 
is greater in differentiated tumors [34]. The most notably 
downregulated microRNAs belong to the families of let-
7, miR-10, miR-26, miR-30, miR-34, miR-99, miR-122, 
miR-123, miR-124, miR-125, miR-140, miR-146, miR-
191, mi-192, miR-219, miR-222 and miR-223. These 
microRNAs are responsible for a variety of cell functions, 
including apoptosis, proliferation, angiogenesis, gene 
expression and stress response. 
Figure 1: Chronic inflammation, a key promoting factor of lung tumorigenesis, is associated to secretion of cytokines 
including tumour necrosis factor α (TNF-α), interleukin 1 (IL-1), IL-6 and IL-8, and molecules such as cyclooxygenase-2 
(COX-2) that are defined as “alarm cytokines”. TNF-α is determinant to initiate and regulate the cytokine cascade by triggering 
the release of IL-1β and IL-6. IL-6 and IL-8 play different roles at a systemic level, being both inducible by IL-1β. IL-6 stimulates 
secretion of C-reactive protein that is an important inflammatory biomarker. High levels of IL-1β in the tumour microenvironment is 
directly associated with bad prognosis, mainly because IL-1β promotes tumour invasiveness by angiogenesis induction, activation of 
myeloid-derived suppressor cells and macrophages type M2.
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It was demonstrated that increasing or decreasing 
the expression of miR-218, one of the microRNAs in 
human airway epithelium most commonly affected by 
smoking, was sufficient to induce a respective change in 
the expression of predicted miR-218 mRNA targets in 
both primary bronchial epithelial cells and H1299 cells. 
On the other hand, the alteration of miR-218 expression 
may influence the expression of MAFG gene targets 
since binding sites for MAFG are overrepresented in the 
epithelial cells of smokers [34]. miR-294, an inhibitor of 
transcriptional repressors, is also affected; it is upregulated 
in an environment with cigarette smoke [33].
When human airway epithelial cells are exposed to 
cigarette smoke condensate, epigenetic repression of miR-
487b expression occurs. This downregulation, together 
with increased expression of miR-487b oncogenic targets 
(SUZ12, BMI1, WNT5A, MYC and KRAS), leads to 
increased proliferation and invasion in LC cells. Thus, 
the repression of miR-487b increases tumorigenesis, 
proliferation and invasion, and the expression of this 
microRNA inhibits the growth and metastatic potential 
of LC [24]. Furthermore, tobacco smoke carcinogens 
can also generate epigenetic silencing, for example, 
the downregulation of miR-200 and miR-205 through 
epigenetic mechanisms, to induce EMT; in these cases, 
EMT was strongly associated with LC [21]. 
Recently, it has been thought that the downregulation 
of microRNAs induced by cigarette smoke could be 
reversed by the oral administration of chemopreventive 
agents (e.g. N-acetylcysteine, oltipraz, indole-3-carbinol, 
5,6-benzoflavone and phenethyl isothiocyanate) [33]. 
According to the authors, these agents could modulate 
proliferation, apoptosis, differentiation, angiogenesis or 
p53 functions. Furthermore, some human polymorphic 
microRNAs that are downregulated by cigarette smoke 
can be protected by these chemopreventive agents. 
For example, phenethyl isothiocyanate can affect the 
downregulation of some of the miRNAs that participate in 
a variety of functions, including the stress response (miR-
125b), NF-kB activation (miR-146-prec), TGF-β expression 
(miR-26a), Ras activation (let-7a, let-7c and miR-192), 
cell apoptosis (miR-99b), cell proliferation (let-7a, 
let-7c and miR-222-prec) and angiogenesis (let-7a, let-7c, 
miR-123-prec and miR-222-prec). The efficacy of these 
agents may be influenced by genetic polymorphisms in 
these miRNAs. The optimal chemopreventive agents 
should not modify the baseline expression of genes and 
should be able to counteract the molecular alterations 
induced by carcinogens, re-establishing a normal 
physiologic situation [35].
MicroRNAs: a brief reference to diagnosis and 
prognosis
Early diagnosis and the adequate treatment of 
each patient with LC are essential in order to improve 
clinical outcomes. Consequently, there is an urgent need 
to identify minimally invasive biomarkers to facilitate 
early diagnosis. Interestingly, microRNAs can be found 
in the nucleus of the cells and in blood. The discovery of 
microRNAs, namely, circulating miRNAs, sheds new light 
on tumor diagnosis and prognosis [36, 37].
Plasma samples from 100 early stage NSCLC 
patients and 100 non-cancer controls were screened for 
754 circulating microRNAs via qRT-PCR using TaqMan 
microRNA arrays. The results revealed that a group of 24 
miRNAs were significantly and independently associated 
with LC development and with predicting and establishing 
risk factors [38]. However, it was shown that a group of 
six microRNAs (miR-30c, miR-616, miR-146b-3p, mi-
566, miR-550 and miR-939) were substantially increased, 
and another two miRNAs (miR-339-5p and miR-656) 
were substantially diminished in the serum of LC patients. 
The increased miRNAs are particularly relevant in the 
earlier stages of disease, suggesting their importance for 
early diagnosis [37].
Plasma miR-195 could be used as a biomarker for 
the early detection and as an independent unfavorable 
prognostic factor for NSCLC since it is downregulated in 
patients with this pathology when compared with healthy 
controls [39]. It was also observed that 10 miRNAs had a 
significantly different expression level in serum of cases 
with NSCLC when 400 NSCLC cases and 220 controls 
were analyzed. Thus, the combination of multiple serum 
miRNAs allows a more accurate cancer diagnosis [36]. 
It was reported that increased plasma levels of miR-
let-7b can be an indicator of survival. Therefore, decreases 
in the plasma expression of let-7b were associated with 
worse prognosis and poorer survival. The reduction in 
serum miR-223 expression was also associated with poor 
survival outcomes in TNM stage I patients. These findings 
showed that LC patients with epigenetic alterations were 
predisposed to more aggressive disease [40]. Considering 
that Let-7 can clinically increase the postoperative survival 
of patients with LC by suppressing tumor proliferation and 
survival through the mediation of oncogenes and other cell 
functions, it has been one of the main potential therapeutic 
targets studied in cancer therapy. Inflammation is one of the 
mechanism clinically affected by Let-7 expression in cancer. 
Molecules related to inflammation, such as NFκB, have are 
involved in the regulatory feedback loop controlling Let-7 
expression in inflammation and cancer. Positive feedback 
occurs when NFκB reduces let-7 levels, inhibiting IL-6 
expression and consequently activating NFκB [13]. 
Additionally, microRNAs can also be used to 
predict the risk of radiation-induced esophageal toxicity 
in patients receiving radiochemotherapy for NSCLC. High 
serum miR-155 and miR-221 levels during the first two 
weeks of radiochemotherapy were associated with the 
development of severe radiation esophagitis. Thus, these 
miRNAs may be useful as important predictors for this 
form of toxicity [41].
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CONCLUSIONS
Despite the high rates of morbidity and mortality 
related to lung cancer (LC), there is still no good early stage 
LC screening. The new data about the roles of microRNA 
alterations in lung disease, including LC, bring new hopes 
for the pathogenesis, diagnosis, treatment and prognosis 
of this cancer. Although tobacco smoking is the main risk 
factor, there are some cases of LC in non-smokers, and only 
a small percentage of smokers will develop LC. Thus, there 
is likely an association of both environmental and genetic 
factors. MicroRNA alterations may play a crucial role in 
lung inflammation and epithelial-mesenchymal transition. 
The levels of serum microRNAs could be employed as 
cancer markers and used in the diagnosis of early stages of 
the disease; they could also be used to predict prognosis, 
maximizing the efficiency of treatment. Chemopreventive 
agents that act in these microRNA alterations can serve as 
new therapeutic targets in some patients with LC in the 
future. Finally, more studies are needed to demonstrate the 
influence of microRNAs in lung inflammation and their use 
in disease screening to improve the quality of life and to 
decrease the mortality of LC patients. 
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